CJC 1295 with DAC vs Without DAC and Which One You Should Actually Use

Most people pick CJC 1295 with DAC because fewer injections feels like the obvious choice, and on the surface that logic makes sense. But the DAC version changes something about how your pituitary responds that has nothing to do with convenience, and understanding that difference is what actually lets you make an informed decision.

Start with the full chain so you have the map.

Your pituitary gland releases growth hormone in pulses, not as a steady stream, and those pulses are triggered by something called GHRH, which stands for growth hormone releasing hormone and is exactly what it sounds like, a signal molecule that tells your pituitary to fire. Between those pulses, growth hormone drops back to a low baseline, and that rhythm, the rise and the fall and the rise again, is how your body is designed to operate. CJC 1295 is a synthetic version of GHRH, so it works by plugging into that same signaling pathway and amplifying the pulses your body is already producing. That is the whole premise of using a secretagogue instead of injecting growth hormone directly.

Now here is where DAC changes things.

DAC stands for drug affinity complex, and it is a chemical modification added to CJC 1295 that allows the molecule to bind to albumin, a protein that circulates in your blood. Albumin itself has a long half-life, and once CJC 1295 binds to it, the peptide gets carried along for the ride instead of being cleared by your kidneys. The result is that CJC 1295 without DAC has a half-life of roughly 30 minutes, and CJC 1295 with DAC has a half-life of somewhere between 5.8 and 8.1 days depending on the study. That is not a small difference. That is a fundamentally different pharmacological profile.

So what actually happens when CJC 1295 with DAC is circulating in your system for a week at a time?

A study by Ionescu and Frohman published in 2006 looked directly at this question and found something important. The pulsatile structure did not disappear. Your pituitary kept firing pulses at roughly the same frequency and magnitude as before. But the trough levels, the low baseline between pulses that is supposed to be there, were elevated 7.5 times above normal. The valleys got filled in. So the waveform stopped looking like a series of sharp peaks and drops and started looking more like elevated flatline with small ripples on top of it.

That distinction matters enormously, and here is why.

Growth hormone does different things depending on how it is delivered, and a study by Surya and colleagues tested this directly in humans by comparing pulsatile versus continuous growth hormone delivery and measuring lipolysis, which is the process your body uses to break down stored fat for fuel. The pulsatile group saw fat breakdown nearly double from a baseline of 4.1 up to 7.1. The continuous group went from 4.1 to 4.8, which was not statistically different from doing nothing at all. Same hormone, same general elevation, completely different outcome based only on the pattern of delivery.

The mechanism behind this comes down to something called receptor downregulation, which is what happens when a cell is exposed to a signal for too long and starts pulling its receptors off the surface to protect itself from being overstimulated. Research from Aleppo and colleagues found that continuous exposure to GHRH for just four hours dropped GHRH receptor expression in pituitary cells to somewhere between 49 and 54 percent of baseline, and the effect was dose-dependent, meaning more exposure caused more receptor loss. The cell was essentially turning down its own sensitivity because the signal would not stop. This is the same biological logic as why you stop hearing background noise after a while. Constant signals get tuned out.

So when CJC 1295 with DAC keeps your GHRH pathway active around the clock for seven days, you are not just elevating the baseline, you are also training the receptors that respond to GHRH to become less sensitive over time, which works against the very mechanism you were trying to amplify in the first place.

The version without DAC sidesteps this because it clears in about 30 minutes. It delivers the pulse, exits, and your pituitary is left to operate on its own between doses. The receptor gets stimulated, then gets a rest, and when the next dose arrives the system is ready to respond again. That is how it was designed to work.

This is also where the comparison to actual growth hormone becomes relevant. If you are going to run continuous elevation anyway, the DAC version puts you in an awkward middle position. You are not getting the pulsatile advantage that makes secretagogues worth using, but you are also not getting the precision that comes with injecting growth hormone directly, where you know exactly how many milligrams you are giving yourself and there are decades of clinical data describing what that dose does. DAC leaves you with the downsides of both approaches and the advantages of neither.

The version without DAC is the one that actually behaves like a secretagogue is supposed to behave, working with your natural rhythm rather than replacing it with something else entirely. It requires more frequent injections and that is a real tradeoff. But the reason you would choose a peptide that stimulates your own production instead of just supplementing with growth hormone directly is specifically because of the pulsatile pattern, and no DAC is the version that preserves it.

Convenience is not a free upgrade if the mechanism you were buying no longer works.

---

References

1. Surya S et al. The pattern of growth hormone delivery to peripheral tissues determines insulin-like growth factor-1 and lipolytic responses in obese subjects. J Clin Endocrinol Metab. 2009;948:2828-2834 — Pulsatile GH nearly doubled lipolysis 7.1 vs 4.1 baseline, continuous was not significantly different from baseline 4.8 vs 4.1. Source
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006;9112:4792-4797 — CJC-1295 DAC preserved pulse frequency and magnitude but elevated basal trough GH 7.5-fold. Source
3. Teichman SL et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;913:799-805 — CJC-1295 DAC half-life 5.8-8.1 days due to albumin binding. Source
4. Aleppo G et al. Homologous down-regulation of growth hormone-releasing hormone receptor messenger ribonucleic acid levels. Endocrinology. 1997;1383:1058-1065 — Continuous GHRH exposure for 4 hours reduced GHRH receptor mRNA to 49-54% of baseline, dose-dependent and cAMP-mediated. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness